change control – Page 34

Labeling mismatch detected during investigation – preventing repeat mix-up events

Addressing Labeling Mismatches During Investigations to Avoid Future Mix-Up Issues Labeling mismatches in pharmaceutical manufacturing can lead to significant quality control issues, regulatory scrutiny, and potential product recalls. This article…

Material mix-up incident reported during investigation – preventing repeat mix-up events

Playbook for Addressing Material Mix-Up Incidents in Pharmaceutical Manufacturing Material mix-up incidents pose significant risks in pharmaceutical manufacturing, potentially resulting in product recalls, regulatory fines, and compromised patient safety. Professionals…

Barcode system failure during investigation – traceability system expectations

Addressing Barcode System Failures: A Playbook for Investigating Traceability Issues In pharmaceutical manufacturing and quality control (QC), maintaining a reliable traceability system is critical for ensuring raw material integrity and…

Supplier change not evaluated during regulatory inspection – regulatory expectations for material changes

Addressing Unassessed Supplier Changes During Regulatory Audits: A Practical Guide Pharmaceutical organizations face the critical responsibility of ensuring that all supplier changes are adequately evaluated before regulatory inspections. Failure to…

Change impact underestimated during regulatory inspection – risk-based change impact assessment

Assessing the Impact of Changes in Raw Materials During Regulatory Inspections In pharmaceutical manufacturing, underestimating the impact of changes to raw materials can lead to severe consequences not only at…

Supplier change not evaluated during supplier change – inspection questions regulators ask

Addressing Supplier Changes: Essential Steps for Compliance and Risk Management Supplier changes can pose significant risks to pharmaceutical manufacturing operations if not properly evaluated. The inability to assess these changes…

Change impact underestimated during deviation investigation – CAPA to prevent repeat failures

Understanding the Underestimated Change Impact in Deviation Investigations In pharmaceutical manufacturing, underestimating the impact of changes during deviation investigations can lead to significant compliance risks, reputation damage, and costly production…

Change control documentation gaps during post-approval change review – regulatory expectations for material changes

Addressing Documentation Gaps in Change Control During Post-Approval Material Changes In the ever-evolving landscape of pharmaceutical manufacturing, change control is a critical process that ensures quality and compliance. However, as…

Change control documentation gaps during supplier change – CAPA to prevent repeat failures

Addressing Gaps in Change Control Documentation During Supplier Transitions In the dynamic pharmaceutical landscape, managing supplier changes is critical for maintaining product quality and regulatory compliance. Frequently, organizations face challenges…

Tag: change control